Syndax Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 184
- Market Cap
- $1.7B
- Introduction
Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.
A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias
- Conditions
- Acute Myeloid Leukemias
- Interventions
- Drug: SNDX-5613Drug: Chemotherapy RegimenDrug: HiDAC
- First Posted Date
- 2024-01-26
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT06226571
- Locations
- 🇺🇸
UCLA Medical Hematology, Burbank, California, United States
🇺🇸City of Hope Medical Center, Duarte, California, United States
🇺🇸AdventHealth Blood & Marrow Transplant Center, Orlando, Florida, United States
MAXPIRe: Study to Evaluate Axatilimab in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- First Posted Date
- 2023-11-15
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 135
- Registration Number
- NCT06132256
- Locations
- 🇦🇺
Sunshine Coast University Hospital, Birtinya, Queensland, Australia
🇦🇺Mater Misericordiae Ltd, South Brisbane, Queensland, Australia
🇦🇺Griffith University Clinical Trial Unit, Southport, Queensland, Australia
Expanded Access Program for Revumenib
- Conditions
- Relapsed/Refractory Acute Leukemia
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Syndax Pharmaceuticals
- Registration Number
- NCT05918913
- Locations
- 🇺🇸
UCLA, UCLA RRMC, Drug Information Center, Department of Pharmaceutical Services Drug Supply Shipment, Los Angeles, California, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid Tumors
- Conditions
- Colorectal CancerSolid Tumors
- Interventions
- Drug: RevumenibDrug: Chemotherapy
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT05731947
- Locations
- 🇺🇸
Honor Health Research Institute, Scottsdale, Arizona, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, Manhattan, New York, United States
Study of Radiolabeled Revumenib in Adults With Acute Leukemia
- First Posted Date
- 2022-06-07
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT05406817
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study of Revumenib in Combination With Chemotherapy in Participants With R/R Acute Leukemia
- Conditions
- Relapsed/Refractory LeukemiasAcute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaMixed Phenotype Acute LeukemiaAcute Myeloid LeukemiaAcute Undifferentiated Leukemia
- Interventions
- First Posted Date
- 2022-04-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT05326516
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of California, San Francisco (UCSF) Benioff Children's Hospital, San Francisco, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 241
- Registration Number
- NCT04710576
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇨🇦Princess Margaret Hospital, Toronto, Ontario, Canada
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
- Conditions
- COVIDCytokine StormCytokine Release SyndromeCoronavirusARDS
- Interventions
- Drug: SNDX-6352Drug: Placebo
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 1
- Registration Number
- NCT04415073
- Locations
- 🇺🇸
HonorHealth, Scottsdale, Arizona, United States
🇺🇸Montefiore Medical Center, Bronx, New York, United States
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Conditions
- Mixed Phenotype Acute LeukemiaAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMixed Lineage Acute LeukemiaAcute Leukemia of Ambiguous Lineage
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 413
- Registration Number
- NCT04065399
- Locations
- 🇫🇷
Hospital Saint-Louis - APHP, Paris, France
🇫🇷Centre Hospitalier Universitaire (CHU) de Bordeaux, Pessac, France
🇩🇪University Hospital Of Ulm, Universitatsklinikum Ulm, Ulm, Baden-Württemberg, Germany
A Phase 1/2 Study to Evaluate Axatilimab in Participants With Active cGVHD
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 41
- Registration Number
- NCT03604692
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸University of Minnesota Medical Center, Minneapolis, Minnesota, United States
🇺🇸University of Miami Miller School of Medicine, Miami, Florida, United States